1. Home
  2. LAW vs KALV Comparison

LAW vs KALV Comparison

Compare LAW & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$3.77

Market Cap

466.2M

Sector

Technology

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$14.99

Market Cap

551.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAW
KALV
Founded
2013
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
466.2M
551.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LAW
KALV
Price
$3.77
$14.99
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$9.00
$30.00
AVG Volume (30 Days)
286.9K
958.2K
Earning Date
02-25-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$152,677,000.00
$1,426,000.00
Revenue This Year
$8.54
N/A
Revenue Next Year
$9.12
$204.16
P/E Ratio
N/A
N/A
Revenue Growth
6.33
N/A
52 Week Low
$3.31
$8.84
52 Week High
$9.11
$19.00

Technical Indicators

Market Signals
Indicator
LAW
KALV
Relative Strength Index (RSI) 14.85 47.11
Support Level $3.61 $14.41
Resistance Level $6.52 $16.59
Average True Range (ATR) 0.41 0.84
MACD -0.26 -0.10
Stochastic Oscillator 5.02 29.66

Price Performance

Historical Comparison
LAW
KALV

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: